The present disclosure relates to an antibody that specifically binds a mutated NT-proBNP having i) a mutation substituting arginine at position 46 with histidine or ii) a mutation substituting glutamic acid at position 43 with aspartic acid. Moreover, the present disclosure relates to a mutated NT-proBNP or fragment thereof. Further, envisaged by the present disclosure are kits containing the antibody of the present disclosure, or the mutated NT-proBNP of the present disclosure. The present disclosure also concerns a method for diagnosing heart failure.

The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD. Also provided herein are methods for treating ALD.

Disclosed are methods for identification of one or more non-native disulfide bonds in a biomolecule (e.g, an antibody). In an example, a method includes performing a digestion of the biomolecule under non-reducing conditions to provide a sample comprising a plurality of biomolecule fragments, contacting the sample to a separation column, applying a first mobile phase gradient comprising trifluoroacetic acid (TFA) and a small molecule additive to the separation column, applying a second mobile phase gradient comprising TFA in acetonitrile (ACN) and a small molecule additive to the separation column, performing a partial reduction procedure on the eluted sample, applying the partially reduced eluted sample components to a mass spectrometer, and performing a mass spectrometric analysis on the partially reduced eluted sample components to identify the one or more non-native disulfide bonds in the biomolecule.

Compositions and methods for identifying glucuronylated protein drug products are provided.

A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.

Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

Provided herein are antibodies specific for Interleukin-1 receptor accessory protein (IL1-RAP).

The present invention provides a highly sensitive in vitro method for diagnosing injury to the central nervous system (CNS), such as a traumatic brain injury (TBI) or stroke. The method involves contacting a sample of blood from a subject suspected of suffering a CNS injury event with at least one antibody capable of detecting a proteolytic fragment of the biomarker Protein Kinase C, gamma isoform (PKCg or PKCγ), which fragment corresponds to a proteolytic fragment of PKCg formed in the excitotoxic environment resulting from neuronal damage. Also disclosed are novel anti-PKCg antibodies useful in the diagnostic methods of the invention to provide diagnosis of CNS injury with essentially 100% accuracy.

Compositions and methods for the detection and identification of Tick-Borne Relapsing Fever Borrelia sp. antibodies.

Provided herein are methods for identification of an expression profile, a transcriptional profile, and/or an epigenetic profile from a cell-containing sample. Also provided are compositions for use in the disclosed methods.